{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:44:29Z","timestamp":1792500269295,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82,073,491"],"award-info":[{"award-number":["82,073,491"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82,373,698"],"award-info":[{"award-number":["82,373,698"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diabet.2025.101696","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T08:22:02Z","timestamp":1755505322000},"page":"101696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Are GLP-1 receptor agonists and diabetic retinopathy foes or friends?"],"prefix":"10.1016","volume":"51","author":[{"given":"Kai","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2025.101696_bib0001","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1007\/s00125-023-05929-0","article-title":"Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy","volume":"66","author":"Tsch\u00f6p","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2025.101696_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2024.101552","article-title":"Cutaneous hypersensitivity reaction to dulaglutide: a case report of an allergic reaction","volume":"50","author":"Samhani","year":"2024","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2025.101696_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116632","article-title":"Binding sites and design strategies for small molecule GLP-1R agonists","volume":"275","author":"Zhang","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.diabet.2025.101696_bib0004","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3949\/ccjm.89a.21110","article-title":"The role of GLP-1 receptor agonists in managing type 2 diabetes","volume":"89","author":"Nachawi","year":"2022","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.diabet.2025.101696_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabet.2025.101696_bib0006","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3803\/EnM.2021.102","article-title":"Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists","volume":"36","author":"Choe","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.diabet.2025.101696_bib0007","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.mcna.2024.03.002","article-title":"Newer outpatient diabetes therapies and technologies","volume":"108","author":"Kamal","year":"2024","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.diabet.2025.101696_bib0008","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1210\/clinem\/dgac276","article-title":"Slow and steady wins the race: 25 years developing the GLP-1 receptor as an effective target for weight loss","volume":"107","author":"Kumar","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101696_bib0009","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1007\/s12325-020-01478-9","article-title":"Oral semaglutide, a new option in the management of type 2 diabetes mellitus: a narrative review","volume":"37","author":"Sofogianni","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabet.2025.101696_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejim.2021.11.008","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: a treatment approach far beyond their glucose-lowering effect","volume":"96","author":"G\u00f3mez-Huelgas","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.diabet.2025.101696_bib0011","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2025.101696_bib0012","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/17425255.2024.2401589","article-title":"Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes","volume":"20","author":"Kukova","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.diabet.2025.101696_bib0013","doi-asserted-by":"crossref","first-page":"413","DOI":"10.36849\/JDD.6550","article-title":"Dermal hypersensitivity reaction to semaglutide: two case reports","volume":"22","author":"Ouellette","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.diabet.2025.101696_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabet.2025.101696_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107770","article-title":"Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: promises and challenges","volume":"216","author":"Zhou","year":"2025","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabet.2025.101696_bib0016","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s10555-024-10192-9","article-title":"The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer","volume":"43","author":"Ibrahim","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.diabet.2025.101696_bib0017","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/cells12091342","article-title":"Retinal cell damage in diabetic retinopathy","volume":"12","author":"Zhou","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.diabet.2025.101696_bib0018","doi-asserted-by":"crossref","DOI":"10.2174\/0115733998274599231109034741","article-title":"Diabetic retinopathy leading to blindness- a review","volume":"20","author":"Kaur","year":"2024","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.diabet.2025.101696_bib0019","first-page":"3584","article-title":"Mechanistic insights into the role of FOXO in diabetic retinopathy","volume":"14","author":"Behl","year":"2022","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.diabet.2025.101696_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6098799","article-title":"observation of curative effect of trimetazidine combined with metoprolol in elderly patients with coronary heart disease complicated with heart failure and the effect of myocardial remodeling by integrated traditional Chinese and western medicine","volume":"2022","author":"Lu","year":"2022","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.diabet.2025.101696_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2025.110236","article-title":"Chidambaram S. miRNAs, piRNAs, and lncRNAs: a triad of non-coding RNAs regulating the neurovascular unit in diabetic retinopathy and their therapeutic potentials","volume":"251","author":"Karpagavalli","year":"2025","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.diabet.2025.101696_bib0022","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/jop.2023.0068","article-title":"Recent insights into the etiopathogenesis of diabetic retinopathy and its management","volume":"40","author":"Biswas","year":"2024","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.diabet.2025.101696_bib0023","article-title":"Diabetic retinopathy: a pharmacological consideration","volume":"15","author":"Maheshwari","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.diabet.2025.101696_bib0024","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1007\/s12035-025-04863-z","article-title":"The role of non-coding RNAs in diabetic retinopathy: mechanistic insights and therapeutic potential","volume":"62","author":"Zuo","year":"2025","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.diabet.2025.101696_bib0025","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.3390\/jcm11206183","article-title":"Will GLP-1 analogues and SGLT-2 inhibitors become new game changers for diabetic retinopathy?","volume":"11","author":"Wo\u0142os-K\u0142osowicz","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabet.2025.101696_bib0026","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12886-023-03155-1","article-title":"Diabetic retinopathy: a comprehensive update on in vivo, in vitro and ex vivo experimental models","volume":"23","author":"Sadikan","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.diabet.2025.101696_bib0027","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2174\/0115733998259940231105200251","article-title":"Diabetic retinopathy - pathophysiology to treatment: a review","volume":"21","author":"Singh","year":"2025","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.diabet.2025.101696_bib0028","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/cells14050376","article-title":"Diabetic retinopathy (DR): mechanisms, current therapies, and emerging strategies","volume":"14","author":"Seo","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.diabet.2025.101696_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1184717","article-title":"Analysis of retinal and choroidal characteristics in patients with early diabetic retinopathy using WSS-OCTA","volume":"14","author":"Qi","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabet.2025.101696_bib0030","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3390\/diagnostics12051234","article-title":"Cardiovascular risk stratification in diabetic retinopathy via atherosclerotic pathway in Covid-19\/non-Covid-19 frameworks using artificial intelligence paradigm: a narrative review","volume":"12","author":"Munjral","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.diabet.2025.101696_bib0031","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.numecd.2020.06.021","article-title":"Aspirin in a diabetic retinopathy setting: insights from NO BLIND study","volume":"30","author":"Pafundi","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.diabet.2025.101696_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.938029","article-title":"Implications of diabetes-induced altered metabolites on retinal neurodegeneration","volume":"16","author":"Aldosari","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.diabet.2025.101696_bib0033","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40662-021-00239-1","article-title":"Neurovascular unit in diabetic retinopathy: pathophysiological roles and potential therapeutical targets","volume":"8","author":"Nian","year":"2021","journal-title":"Eye Vis (Lond)"},{"key":"10.1016\/j.diabet.2025.101696_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.937999","article-title":"Neuroinflammation and neurodegeneration in diabetic retinopathy","volume":"14","author":"Bianco","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.diabet.2025.101696_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.862325","article-title":"Redox and calcium alterations of a muller cell line exposed to diabetic retinopathy-like environment","volume":"16","author":"Rosato","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.diabet.2025.101696_bib0036","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/14740338.2021.1887136","article-title":"Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy","volume":"20","author":"Dauner","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.diabet.2025.101696_bib0037","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17446651.2025.2459720","article-title":"Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data","volume":"20","author":"Singh","year":"2025","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101696_bib0038","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/j.apsb.2024.03.011","article-title":"Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling","volume":"14","author":"He","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.diabet.2025.101696_bib0039","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","article-title":"Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record data study","volume":"265","author":"Wai","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.diabet.2025.101696_bib0040","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.3390\/jcm13061797","article-title":"Novel antidiabetic drugs and the risk of diabetic retinopathy: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Ma\u0142yszczak","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabet.2025.101696_bib0041","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12916-023-02753-6","article-title":"Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and mendelian randomization studies","volume":"21","author":"Zheng","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.diabet.2025.101696_bib0042","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2174\/1574886318666230420084701","article-title":"Association between glucose-lowering treatments and risk of diabetic retinopathy in people with type 2 diabetes: a nationwide cohort study","volume":"19","author":"Hasselstr\u00f8m Jensen","year":"2024","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.diabet.2025.101696_bib0043","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1111\/dom.15788","article-title":"Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a population-based cohort study","volume":"26","author":"Lin","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101696_bib0044","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/09286586.2024.2399764","article-title":"Van der Beek BL. Glucagon-like peptide-1 receptor agonists are not associated with an increased risk of progressing to vision-threatening diabetic retinopathy","volume":"32","author":"Tauqeer","year":"2025","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.diabet.2025.101696_bib0045","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40261-023-01319-x","article-title":"Glucagon-like peptide-1 receptor agonist and risk of diabetic retinopathy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"43","author":"Jiao","year":"2023","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.diabet.2025.101696_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100547","article-title":"The effect of glucagon-like peptide-1 receptor agonists on diabetic retinopathy at a tertiary care center","volume":"4","author":"Joo","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.diabet.2025.101696_bib0047","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc20-1815","article-title":"HbA(1c) change and diabetic retinopathy during glp-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression","volume":"44","author":"Bethel","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101696_bib0048","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000004507","article-title":"Real-world associations between GLP-1 receptor agonist use and diabetic retinopathy accounting for longitudinal glycemic control","author":"Talebi","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.diabet.2025.101696_bib0049","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MNH.0000000000000976","article-title":"Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression","volume":"33","author":"Jr","year":"2024","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.diabet.2025.101696_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171240","article-title":"Glucagon-like peptide 1 receptor agonist use and the effect on diabetic retinopathy: an uncertain relationship","volume":"178","author":"Hui","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.diabet.2025.101696_bib0051","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00417-023-06236-5","article-title":"Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review","volume":"262","author":"Ntentakis","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.diabet.2025.101696_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102696","article-title":"Glucagon-like peptide 1-receptor agonists and A1c: good for the heart but less so for the eyes?","volume":"17","author":"Albert","year":"2023","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.diabet.2025.101696_bib0053","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/ICU.0000000000001137","article-title":"Glucagon-like peptide-1 receptor agonists and the eye","volume":"36","author":"Zhang","year":"2025","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.diabet.2025.101696_bib0054","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1248\/yakushi.21-00158-2","article-title":"Role of the blood-retinal barrier transporters: antiaging in retina","volume":"141","author":"Hosoya","year":"2021","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.diabet.2025.101696_bib0055","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s12264-022-00826-9","article-title":"Signaling mechanism for modulation by GLP-1 and exendin-4 of GABA receptors on rat retinal ganglion cells","volume":"38","author":"Zhang","year":"2022","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.diabet.2025.101696_bib0056","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12886-022-02413-y","article-title":"Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats","volume":"22","author":"Inoue","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.diabet.2025.101696_bib0057","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.diabet.2025.101696_bib0058","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012428","article-title":"Anti-inflammatory effects of GLP-1R activation in the retina","volume":"23","author":"Puddu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabet.2025.101696_bib0059","doi-asserted-by":"crossref","DOI":"10.1007\/s12013-025-01742-1","article-title":"The impact of liraglutide, a GLP-1 receptor agonist, on high glucose-induced inflammation, apoptosis, oxidative stress, and NLRP3 signaling","author":"Gokce","year":"2025","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.diabet.2025.101696_bib0060","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","article-title":"Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy","volume":"66","author":"Goldney","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2025.101696_bib0061","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.3390\/ijms26073050","article-title":"GLP-1 receptor agonists and myocardial perfusion: bridging mechanisms to clinical outcomes","volume":"26","author":"Karakasis","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabet.2025.101696_bib0062","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1861940","article-title":"GLP-1 RA improves diabetic retinopathy by protecting the blood-retinal barrier through GLP-1R-ROCK-p-MLC signaling pathway","volume":"2022","author":"Wei","year":"2022","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.diabet.2025.101696_bib0063","doi-asserted-by":"crossref","first-page":"9591","DOI":"10.3390\/ijms24119591","article-title":"Current treatments for diabetic macular edema","volume":"24","author":"Tatsumi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabet.2025.101696_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175896","article-title":"Exendin-4 protects against high glucose-induced mitochondrial dysfunction and oxidative stress in SH-SY5Y neuroblastoma cells through GLP-1 receptor\/Epac\/Akt signaling","volume":"954","author":"Pandey","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.diabet.2025.101696_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.824054","article-title":"Glucagon-like peptide 1 receptor agonists - potential game changers in the treatment of glaucoma?","volume":"16","author":"Mouhammad","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.diabet.2025.101696_bib0066","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12825","article-title":"Beneficial effects of empagliflozin and liraglutide on the cerebral microcirculation of diabetic rats","volume":"30","author":"d'Avila","year":"2023","journal-title":"Microcirculation"},{"key":"10.1016\/j.diabet.2025.101696_bib0067","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11606-021-07105-9","article-title":"the longer-term benefits and harms of glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis","volume":"37","author":"Alexander","year":"2022","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.diabet.2025.101696_bib0068","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.589114","article-title":"Neuroprotective role of GLP-1 analog for retinal ganglion cells via PINK1\/parkin-mediated mitophagy in diabetic retinopathy","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabet.2025.101696_bib0069","doi-asserted-by":"crossref","first-page":"800","DOI":"10.4103\/NRR.NRR-D-24-00001","article-title":"Topical administration of GLP-1 eyedrops improves retinal ganglion cell function by facilitating presynaptic GABA release in early experimental diabetes","volume":"21","author":"Shao","year":"2026","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.diabet.2025.101696_bib0070","first-page":"2332","article-title":"Comprehensive review of glucagon-like peptide 1 receptor agonist treatment on the risk of cardiovascular outcomes and retinopathy as diabetic complications","volume":"27","author":"Liu","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.diabet.2025.101696_bib0071","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93382","article-title":"Myeloid cell modulation by a GLP-1 receptor agonist regulates retinal angiogenesis in ischemic retinopathy","volume":"6","author":"Zhou","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.diabet.2025.101696_bib0072","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1156829","article-title":"Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma","volume":"17","author":"Lawrence","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.diabet.2025.101696_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175269","article-title":"Anti-inflammatory effect of glucagon-like peptide-1 receptor agonist on the neurosensory retina in an acute optic nerve injury rat model","volume":"933","author":"Chung","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.diabet.2025.101696_bib0074","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00592-023-02135-7","article-title":"The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy","volume":"60","author":"Oezer","year":"2023","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabet.2025.101696_bib0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ajo.2024.08.030","article-title":"Association between glucagon-like peptide-1 receptor agonists exposure and intraocular pressure change: GLP-1 receptor agonists and intraocular pressure change","volume":"269","author":"Hallaj","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.diabet.2025.101696_bib0076","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1303238","article-title":"Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis","volume":"14","author":"Tan","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabet.2025.101696_bib0077","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00125-024-06132-5","article-title":"Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database","volume":"67","author":"Eleftheriadou","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2025.101696_bib0078","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.2147\/DMSO.S242148","article-title":"association between abnormal glycemic phenotypes and microvascular complications of type 2 diabetes mellitus outpatients in China","volume":"13","author":"Liu","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.diabet.2025.101696_bib0079","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4239\/wjd.v13.i6.466","article-title":"Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors","volume":"13","author":"Singh","year":"2022","journal-title":"World J Diabetes"},{"key":"10.1016\/j.diabet.2025.101696_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108255","article-title":"Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis","volume":"36","author":"Yoshida","year":"2022","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabet.2025.101696_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112083","article-title":"Tirzepatide and major adverse limb events: insights from a multicenter real-world analysis in PAD and diabetes patients","volume":"222","author":"Wu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2025.101696_bib0082","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12020-024-04112-8","article-title":"Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database","volume":"88","author":"Zhou","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.diabet.2025.101696_bib0083","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14740338.2024.2419989","article-title":"Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology","volume":"24","author":"Luo","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.diabet.2025.101696_bib0084","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4093\/dmj.2022.0221","article-title":"Risk of diabetic retinopathy between sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists","volume":"47","author":"Lin","year":"2023","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabet.2025.101696_bib0085","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.oret.2024.05.003","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas for sight-threatening diabetic retinopathy","volume":"8","author":"Barkmeier","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.diabet.2025.101696_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.103099","article-title":"Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: a propensity based cohort study","volume":"18","author":"Yen","year":"2024","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.diabet.2025.101696_bib0087","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S2213-8587(24)00371-1","article-title":"GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study","volume":"13","author":"Orandi","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2025.101696_bib0088","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1507\/endocrj.EJ25-0087","article-title":"Physiology and clinical applications of GIP","volume":"72","author":"Yamane","year":"2025","journal-title":"Endocr J"},{"key":"10.1016\/j.diabet.2025.101696_bib0089","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ando.2022.12.423","article-title":"Dual GIP\/GLP-1 receptor agonists: new advances for treating type-2 diabetes","volume":"84","author":"Scheen","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.diabet.2025.101696_bib0090","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3803\/EnM.2024.1940","article-title":"Glucagon-like peptide-1 based therapies: a new horizon in obesity management","volume":"39","author":"Son","year":"2024","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.diabet.2025.101696_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2025.171380","article-title":"Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities","volume":"187","author":"Bailey","year":"2025","journal-title":"Peptides"},{"key":"10.1016\/j.diabet.2025.101696_bib0092","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/dom.16106","article-title":"Why does GLP-1 agonist combined with GIP and\/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?","volume":"27","author":"Jiang","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101696_bib0093","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqad153","article-title":"Beaudry JL. Synergistic combinations of gut- and pancreas-hormone-based therapies: advancements in treatments for metabolic diseases","volume":"164","author":"Lyons","year":"2023","journal-title":"Endocrinology"},{"key":"10.1016\/j.diabet.2025.101696_bib0094","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1004044","article-title":"Clinical perspectives on the use of the GIP\/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity","volume":"13","author":"Gallwitz","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabet.2025.101696_bib0095","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-23-0404","article-title":"Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges","volume":"262","author":"Huang","year":"2024","journal-title":"J Endocrinol"},{"key":"10.1016\/j.diabet.2025.101696_bib0096","article-title":"Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice","volume":"10","author":"Hammoud","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.diabet.2025.101696_bib0097","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3803\/EnM.2024.1942","article-title":"The road towards triple agonists: glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and glucagon receptor - an update","volume":"39","author":"Jakubowska","year":"2024","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.diabet.2025.101696_bib0098","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13543784.2025.2472408","article-title":"The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines","volume":"34","author":"Madsbad","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.diabet.2025.101696_bib0099","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/biomedicines12061320","article-title":"New developments in pharmacological treatment of obesity and type 2 diabetes-beyond and within GLP-1 receptor agonists","volume":"12","author":"Sztanek","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.diabet.2025.101696_bib0100","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101696_bib0101","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111675","article-title":"Incretin-based investigational therapies for the treatment of MASLD\/MASH","volume":"211","author":"Brouwers","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2025.101696_bib0102","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202410237","article-title":"Potent and protease resistant azapeptide agonists of the GLP-1 and GIP receptors","volume":"63","author":"Dinsmore","year":"2024","journal-title":"Angew Chem Int Ed Engl"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:30:43Z","timestamp":1772883043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363625000904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1262363625000904"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101696","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are GLP-1 receptor agonists and diabetic retinopathy foes or friends?","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101696"}}